A2A Pharmaceuticals
A2A Pharmaceuticals is a clinical-stage biotech using its proprietary SCULPT computational/AI platform to design small-molecule PPI inhibitors for oncology, autoimmune, anti-infective, and rare-disease indications, monetizing via co-development and licensing deals with larger pharma partners.
- Company typePrivate
- Founded2017
- HeadquartersNew York, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What A2A Pharmaceuticals does
A2A Pharmaceuticals Inc. is a privately held, clinical-stage biotechnology company founded in 2017 (incorporated and headquartered in New York with an additional site at the Cambridge Innovation Center) that uses its proprietary SCULPT platform — a fragment-based computational drug design process enhanced with multiple AI tools — to generate small molecule libraries of thousands to millions of compounds against historically difficult targets, particularly protein-protein interactions (PPIs). Its pipeline spans oncology (TACC3/AO-252 in Phase 1 for ovarian, triple negative breast and endometrial cancer; MLL-Menin inhibitors via the Biomea Fusion JV; YAP-TEAD and KRAS degraders in preclinical), autoimmune disease (TYK2 pseudokinase inhibitor), anti-infectives (a SCULPT-derived antibiotic program for gram-negative bacteria), and rare disease (Duchenne muscular dystrophy).
The company operates a platform-plus-pipeline model monetized primarily through co-development agreements, licensing deals, and strategic partnerships with larger pharmaceutical companies — including a multi-target agreement with Daewoong Pharmaceutical (2020), a 50-50 joint venture with Biomea Fusion for the MLL-Menin program (subsequently IPO'd as BMEA), and an exclusive worldwide license of AO-252 to AIM-listed Coiled Therapeutics (2026) — supplemented historically by service-style pilot projects completed for multiple larger pharma counterparties in 2017. The company is venture-backed (seeded by SOSV/IndieBio; ~$8M total disclosed financing through 2019), operates with 1–10 employees, and relies on outsourced CRO and AI partners (WuXi AppTec, Charles River, Insilico Medicine) to scale development beyond its internal team.
A2A Pharmaceuticals firmographics
Firmographics- Name
- A2A Pharmaceuticals
- Legal name
- A2A Pharmaceuticals Inc.
- Website
- https://a2apharma.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- A2A Pharmaceuticals is a clinical-stage biotech using its proprietary SCULPT computational/AI platform to design small-molecule PPI inhibitors for oncology, autoimmune, anti-infective, and rare-disease indications, monetizing via co-development and licensing deals with larger pharma partners.
- Ownership category
- akta.pro rank
A2A Pharmaceuticals industry classification
Industry- Product category
- Clinical-stage Oncology Pharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
- akta.pro secondary industries
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
Keywords
Where A2A Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
A2A Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Drug Development Partnerships: A2A Pharmaceuticals generates revenue through co-development agreements, licensing deals, and strategic partnerships with larger pharmaceutical companies. The company has formed partnerships with Daewoong Pharmaceutical for AI-enhanced oncology drug discovery and Biomea Fusion for the MLL-Menin program.
- Pilot Projects: Revenue generating pilot projects for multiple larger pharmaceutical companies completed in 2017.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
A2A Pharmaceuticals product offering
Product offeringCore offering
A2A Pharmaceuticals uses its proprietary SCULPT™ (Systematic Combinatorial Unification of chemical groups into Libraries against a Pharmacological Target) computational drug design platform—enhanced with multiple AI tools—to design and develop novel small molecule drug candidates that target challenging protein-protein interactions (PPIs) and other difficult-to-drug targets. Its clinical-stage pipeline is led by AO-252, a first-in-class TACC3 PPI inhibitor in Phase 1 trials for women's cancers, with additional programs in oncology, autoimmune disorders, and anti-infectives developed through co-development agreements and licensing partnerships with larger pharmaceutical companies.
Product overview
A2A Pharmaceuticals is a clinical-stage oncology company operating a platform-plus-pipeline model centered on its proprietary SCULPT™ computational drug design platform. The SCULPT platform uses fragment-based computational approaches enhanced with multiple AI tools to design novel small molecule libraries targeting protein-protein interactions (PPIs). The company's pipeline includes multiple drug programs at various clinical and preclinical stages: lead asset AO-252 (TACC3 inhibitor) is in Phase 1 for women's cancers; MLL-Menin inhibitors partnered with Biomea Fusion entered clinical trials in 2021; and preclinical programs include TYK2 pseudokinase inhibitors (autoimmune), YAP-TEAD inhibitors/degraders, and KRAS degraders targeting broad cancer populations.
Differentiator
Problem solved
Functional benefit
Products and services
- AO-252 TACC3 Inhibitor
- MLL-Menin Inhibitors
- TYK2 Pseudokinase Inhibitor
- YAP-TEAD Inhibitor/Degrader
- KRAS Degrader
Quantifiable outcome
- 22% average tumor reduction over approximately 2 months in 67% of patients (BID cohort at 160mg dose)
- +2 more outcomes
Companies that use A2A Pharmaceuticals
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles1 record
A2A Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature8 records
A2A Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core, major, supporting and minor.
- Biomea Fusioncore50-50 JV formation for taking A2A's MLL-Menin program into the clinic. Biomea Fusion was co-founded by A2A and later spun off as a public company (NASDAQ: BMEA) raising $56M Series A. Collaboration for novel molecules with better drug-like properties, selectivity, and potency than competitive molecules.
- Daewoong PharmaceuticalmajorMulti-target co-development agreement for AI-enhanced oncology drug discovery. A2A Pharmaceuticals and Daewoong Pharmaceutical are collaborating on multiple oncology targets using A2A's SCULPT platform and AI capabilities.
- Wuxi AppTecsupportingListed as a partner, suggesting collaboration for contract research or pharmaceutical services.
- Charles River LaboratoriessupportingListed as a partner, suggesting collaboration for preclinical/clinical development services.
- Insilico MedicinesupportingCollaboration mentioned with Insilico Medicine to advance new drug candidates toward IND. Part of network of experienced collaborators including former management of Pharmacyclics, Novartis, J&J, and P&G.
- CPSminorListed as a partner in logo section; specific relationship details not available.
Scale indicators7 records
Recent moves7 records
Expansion highlights5 records
A2A Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Foghorn Therapeutics: Clinical-stage oncology company developing medicines against chromatin regulatory targets, including YAP-TEAD inhibitors in cancer. Directly comparable to A2A's YAP-TEAD program and overall PPI/epigenetic target approach.
- Schrödinger: Computational chemistry platform combining physics-based simulation with ML for drug discovery. Direct competitor in computational small-molecule design with broader platform offering and stronger financial base.
- Exscientia: AI-driven precision medicine company combining patient-derived data with AI-designed drug candidates in oncology and beyond. Direct competitor in AI-designed small molecule development for pharma partners.
- Insilico Medicine: AI-driven drug discovery platform advancing multiple internal and partnered programs, including oncology and immunology targets. A2A lists Insilico as a collaborator, and both apply generative AI/ML to small-molecule design for challenging targets.
- Recursion Pharmaceuticals: AI-driven drug discovery company using a high-throughput biology platform to identify novel targets and drug candidates across oncology and other indications. Closely comparable to A2A in applying computational/AI methods to accelerate early-stage drug discovery.
- Biomea Fusion: Public precision oncology company (NASDAQ: BMEA) that A2A co-founded through a 50-50 JV for the MLL-Menin program. Closely tied — Biomea is both an A2A spinout and a direct competitor for clinical-stage menin-MLL assets.
- C4 Therapeutics: Clinical-stage biopharmaceutical company developing targeted protein degraders (including KRAS degraders) for cancer treatment. Closely comparable to A2A's KRAS degrader program and broader degrader-based pipeline approach.
Broad incumbents
- Revolution Medicines: Clinical-stage oncology company developing RAS(ON) inhibitors targeting multiple KRAS mutations. Direct competitive threat to A2A's KRAS degrader strategy, with substantially more clinical progress.
- Mirati Therapeutics: KRAS-focused oncology company (now part of Bristol-Myers Squibb) with approved and clinical-stage mutation-specific KRAS inhibitors. Represents the benchmark competition A2A's pan-KRAS degrader aims to differentiate against.
- Arvinas: Pioneer in targeted protein degradation with clinical-stage PROTAC degraders. A more established player in the degrader space that A2A's KRAS degrader program would compete with for partnership and capital.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights7 records
Customer concentration
A2A Pharmaceuticals social profiles
Digital presenceA2A Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
A2A Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles4 records
A2A Pharmaceuticals subsidiaries and ownership
Company hierarchySubsidiaries1 record
A2A Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
A2A Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about A2A Pharmaceuticals
What does A2A Pharmaceuticals do?
A2A Pharmaceuticals uses its proprietary SCULPT™ (Systematic Combinatorial Unification of chemical groups into Libraries against a Pharmacological Target) computational drug design platform—enhanced with multiple AI tools—to design and develop novel small molecule drug candidates that target challenging protein-protein interactions (PPIs) and other difficult-to-drug targets. Its clinical-stage pipeline is led by AO-252, a first-in-class TACC3 PPI inhibitor in Phase 1 trials for women's cancers, with additional programs in oncology, autoimmune disorders, and anti-infectives developed through co-development agreements and licensing partnerships with larger pharmaceutical companies.
Is A2A Pharmaceuticals a public or private company?
A2A Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was A2A Pharmaceuticals founded?
A2A Pharmaceuticals was founded in 2017. It employs 1 to 10 people.
Where is A2A Pharmaceuticals based?
A2A Pharmaceuticals is headquartered in New York, United States, in the North America region.
How does A2A Pharmaceuticals make money?
Two revenue lines are on record. Drug Development Partnerships are the primary driver. The others are pilot Projects.
Who are A2A Pharmaceuticals's main competitors?
Direct peers on record are Foghorn Therapeutics, Schrödinger, Exscientia, Insilico Medicine, Recursion Pharmaceuticals, Biomea Fusion and C4 Therapeutics. Broad incumbents are Revolution Medicines, Mirati Therapeutics and Arvinas.
Does A2A Pharmaceuticals have an API?
No public API is recorded for A2A Pharmaceuticals.
What industry is A2A Pharmaceuticals in?
A2A Pharmaceuticals's product category is Clinical-stage Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 8731.